PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18366295-2	2008	In study populations comprising primarily good- and intermediate-risk patients with clear cell renal cell carcinoma and prior nephrectomy, prolonged progression-free survival was demonstrated for three angiogenesis-targeted agents: sunitinib (compared with interferon [IFN]), bevacizumab plus IFN (vs IFN alone) and sorafenib (vs placebo in cytokine-refractory patients).	Sunitinib	232-241	interferon alpha 1	Homo sapiens	293-296	
18366295-2	2008	In study populations comprising primarily good- and intermediate-risk patients with clear cell renal cell carcinoma and prior nephrectomy, prolonged progression-free survival was demonstrated for three angiogenesis-targeted agents: sunitinib (compared with interferon [IFN]), bevacizumab plus IFN (vs IFN alone) and sorafenib (vs placebo in cytokine-refractory patients).	Sunitinib	232-241	interferon alpha 1	Homo sapiens	293-296	
30381648-11	2018	As a result, the ICER associated with replacing IFN-alpha with sunitinib was 22,695,839 yen/QALYs.	Sunitinib	63-72	interferon alpha 1	Homo sapiens	48-57	
17621562-6	2007	A recent Phase III study evaluating sunitinib as first-line therapy showed a significant difference when compared to interferonalfa (IFN-alpha) for a progression-free survival of 11 months in the sunitinib arm and 5 months in the IFN-alpha arm (hazard ratio 0.42; 95% CI 0.32-0.54; P50.001).	Sunitinib	36-45	interferon alpha 1	Homo sapiens	230-239	
23679326-14	2013	In our study, we observed second line sunitinib treatment following IFN-alpha to be effective and tolerable.	Sunitinib	38-47	interferon alpha 1	Homo sapiens	68-77	
23819366-6	2013	Sunitinib was administered following Interferon alpha (IFN-alpha) therapy; however, the lung metastases became larger, so administration of everolimus at 10 mg/day was commenced.	Sunitinib	0-9	interferon alpha 1	Homo sapiens	55-64	
23329590-13	2013	Based upon the work presented including a 12.5 % discount for pazopanib, sunitinib was extendedly dominated by a combination of pazopanib and IFN-alpha.	Sunitinib	73-82	interferon alpha 1	Homo sapiens	142-151	
19568242-14	2009	CONCLUSION: There is evidence to suggest that treatment with sunitinib and treatment with bevacizumab plus IFN has clinically relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC.	Sunitinib	61-70	interferon alpha 1	Homo sapiens	196-199	
21704235-11	2011	An indirect comparison suggests that sunitinib is likely to demonstrate greater clinical benefit than sorafenib in terms of PFS (HR = 0.47; 95% CI, 0.316-0.713; P < 0.001), using IFN-alpha as the comparator.	Sunitinib	37-46	interferon alpha 1	Homo sapiens	182-191	
21265994-4	2011	RESULTS:   Sunitinib was more effective and less costly than sorafenib (gains of 0.52 PFLYs, 0.16 LYs and 0.17 QALYs and savings/patient of $13,576 in the US) and bevacizumab plus IFN-alpha (gains of 0.19 PFLYs, 0.23 LYs and 0.16 QALYs in both countries and savings/patient of $67,798 and $47,264 in the US and Sweden, respectively).	Sunitinib	11-20	interferon alpha 1	Homo sapiens	180-189	
19127560-11	2009	CONCLUSIONS: The introduction of first-line sunitinib was associated with a doubling of overall survival compared with patients treated with IFN alone.	Sunitinib	44-53	interferon alpha 1	Homo sapiens	141-144	
19213665-1	2009	BACKGROUND: Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor that has demonstrated superior efficacy over interferon (IFN)-alpha in a phase III trial in first-line, metastatic renal cell carcinoma (RCC).	Sunitinib	12-28	interferon alpha 1	Homo sapiens	126-148	
18711190-7	2008	RESULTS: Treatment with sunitinib is associated with a gain in progression-free years of 0.41 and 0.35 over IFN-alpha and IL-2.	Sunitinib	24-33	interferon alpha 1	Homo sapiens	108-117	
18711190-9	2008	Both IFN-alpha and sunitinib treatments dominate IL-2 treatment; the incremental cost-effectiveness ratio of sunitinib versus IFN-alpha was $18,611 per progression-free year gained and $67,215 per LY gained, and the cost-utility ratio is $52,593 per QALY gained (at a 5% discount rate).	Sunitinib	109-118	interferon alpha 1	Homo sapiens	5-14